MediciNova Inc., a biopharmaceutical company listed on the NASDAQ Global Market and the Tokyo Stock Exchange, has announced the successful enrollment of the target number of participants in its COMBAT-ALS Phase 2b/3 clinical trial. This trial is evaluating the efficacy of MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). The study has enrolled participants across multiple sites in the United States and Canada. The achievement of this enrollment milestone enables the company to proceed to the next phase of the trial. The results of this study have not yet been presented and will be disclosed in the future.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9518347-en) on August 26, 2025, and is solely responsible for the information contained therein.